Purdue Pharma Defeats State Pushback to Opioid Settlement Vote
- Judge puts aside concerns about plan’s feasibility for now
- OxyContin maker to solicit votes on opioid deal pending tweaks
Photographer: George Frey/Bloomberg
This article is for subscribers only.
Purdue Pharma LP’s plan to unload opioid claims cleared a key hurdle Wednesday, with the OxyContin maker overcoming an objection from more than 20 U.S. states.
After a six-hour hearing, U.S. Bankruptcy Judge Robert Drain said an outline of Purdue’s settlement plan should be ready to send to creditors for a vote by next week. Drain pushed aside objections from a group of state attorneys general who argued the plan is so flawed it should be stopped in its tracks.